Zokinvy
Active Ingredient(s): LonafarnibFDA Approved: * November 20, 2020
Pharm Company: * EIGER BIOPHARMS
Category: Genetic Disorders
* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".
Zokinvy Overview
Lonafarnib, sold under the brand name Zokinvy, is a medication used to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain processing-deficient progeroid laminopathies in people one year of age and older.[1] The most common side effects included nausea vomiting, diarrhea, infection, decreased appetite and fatigue.[1] Contents 1 Medical uses 2 Contraindications 3 History 4 Research 5 References 6 External links...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lonafarnib
Recent Zokinvy Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Lonafarnib
- Capsule: 50mg, 75mg